Showing results (311-320 of 333) with videos related to

Sort By:
Pageof 34
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 2, 2025
First-Line Lorlatinib Versus Crizotinib in Asian Patients With Advanced ALK-Positive NSCLC: Five-Year Outcomes From the CROWN StudyYi-Long Wu, Hye Ryun Kim, Ross A Soo, et al.
Nature Medicine|January 15, 2020
Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alterationAlexander Drilon, Jeffrey W Clark, Jared Weiss, et al.
The Journal of Clinical Investigation|April 1, 2024
Soluble immune checkpoint factors reflect exhaustion of antitumor immunity and response to PD-1 blockadeHidetoshi Hayashi, Kenji Chamoto, Ryusuke Hatae, et al.
JAMA Oncology|December 21, 2023
Atezolizumab and Platinum Plus Pemetrexed With or Without Bevacizumab for Metastatic Nonsquamous Non-Small Cell Lung Cancer: A Phase 3 Randomized Clinical TrialYoshimasa Shiraishi, Junji Kishimoto, Shunichi Sugawara, et al.
JTO Clinical and Research Reports|May 24, 2023
Asian Subgroup Analysis of the Randomized Phase 3 CROWN Study of First-Line Lorlatinib Versus Crizotinib in Advanced ALK-Positive NSCLCQing Zhou, Ross A Soo, Gee-Chen Chang, et al.
Cancer Science|October 24, 2021
Predictive value of EGFR mutation in non-small-cell lung cancer patients treated with platinum doublet postoperative chemotherapyToshiaki Takahashi, Kazuko Sakai, Hirotsugu Kenmotsu, et al.
British Journal of Cancer|March 9, 2024
Anti-integrin αvβ6 autoantibodies are a potential biomarker for ulcerative colitis-like immune checkpoint inhibitor-induced colitisMasataka Yokode, Masahiro Shiokawa, Hisato Kawakami, et al.
Lung Cancer (Amsterdam, Netherlands)|April 29, 2025
Amivantamab plus lazertinib versus osimertinib as first-line treatment in EGFR-mutated advanced non-small cell lung cancer: MARIPOSA Asian subsetByoung Chul Cho, Hidetoshi Hayashi, Jong-Seok Lee, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 14, 2025
A pooled analysis of datopotamab deruxtecan in patients with EGFR-mutated NSCLCMyung-Ju Ahn, Aaron Lisberg, Yasushi Goto, et al.
The Lancet. Respiratory Medicine|August 19, 2024
Comparison of platinum combination chemotherapy plus pembrolizumab versus platinum combination chemotherapy plus nivolumab-ipilimumab for treatment-naive advanced non-small-cell lung cancer in Japan (JCOG2007): an open-label, multicentre, randomised, phase 3 trialYoshimasa Shiraishi, Shogo Nomura, Shunichi Sugawara, et al.
Pageof 34